- Home
- ABOS vs KPTI Comparison
ABOS vs KPTI Comparison
Compare ABOS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- KPTI
- Stock Information
- Founded
- ABOS 1996
- KPTI 2008
- Country
- ABOS United States
- KPTI United States
- Employees
- ABOS N/A
- KPTI N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- KPTI Health Care
- Exchange
- ABOS Nasdaq
- KPTI Nasdaq
- Market Cap
- ABOS 83.5M
- KPTI 81.1M
- IPO Year
- ABOS 2021
- KPTI 2013
- Fundamental
- Price
- ABOS $1.39
- KPTI $0.60
- Analyst Decision
- ABOS Strong Buy
- KPTI Strong Buy
- Analyst Count
- ABOS 3
- KPTI 4
- Target Price
- ABOS $9.33
- KPTI $5.00
- AVG Volume (30 Days)
- ABOS 232.9K
- KPTI 840.0K
- Earning Date
- ABOS 03-25-2025
- KPTI 02-19-2025
- Dividend Yield
- ABOS N/A
- KPTI N/A
- EPS Growth
- ABOS N/A
- KPTI N/A
- EPS
- ABOS N/A
- KPTI N/A
- Revenue
- ABOS N/A
- KPTI $145,237,000.00
- Revenue This Year
- ABOS N/A
- KPTI $4.47
- Revenue Next Year
- ABOS N/A
- KPTI $7.35
- P/E Ratio
- ABOS N/A
- KPTI N/A
- Revenue Growth
- ABOS N/A
- KPTI N/A
- 52 Week Low
- ABOS $1.28
- KPTI $0.53
- 52 Week High
- ABOS $5.09
- KPTI $1.70
- Technical
- Relative Strength Index (RSI)
- ABOS 37.15
- KPTI 41.56
- Support Level
- ABOS $1.36
- KPTI $0.53
- Resistance Level
- ABOS $1.52
- KPTI $0.64
- Average True Range (ATR)
- ABOS 0.08
- KPTI 0.05
- MACD
- ABOS 0.01
- KPTI -0.00
- Stochastic Oscillator
- ABOS 40.30
- KPTI 44.13
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.